These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 7690450

  • 21. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain.
    Flynn DD, Mash DC.
    Synapse; 1993 Aug; 14(4):283-96. PubMed ID: 8248852
    [Abstract] [Full Text] [Related]

  • 22. Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an "infinite dilution" procedure.
    Christopoulos A, Lanzafame A, Ziegler A, Mitchelson F.
    Biochem Pharmacol; 1997 Mar 21; 53(6):795-800. PubMed ID: 9113100
    [Abstract] [Full Text] [Related]

  • 23. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors.
    Gnagey AL, Seidenberg M, Ellis J.
    Mol Pharmacol; 1999 Dec 21; 56(6):1245-53. PubMed ID: 10570052
    [Abstract] [Full Text] [Related]

  • 24. Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the m1 muscarinic receptor.
    Lee NH, Hu J, el-Fakahany EE.
    J Pharmacol Exp Ther; 1992 Jul 21; 262(1):312-6. PubMed ID: 1625205
    [Abstract] [Full Text] [Related]

  • 25. Competitive and allosteric interactions of 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-11H-di benzo[b,e][1, 4]diazepine-11-one hydrochloride (UH-AH 37) at muscarinic receptors, via distinct epitopes.
    Ellis J, Seidenberg M.
    Biochem Pharmacol; 1999 Jan 15; 57(2):181-6. PubMed ID: 9890566
    [Abstract] [Full Text] [Related]

  • 26. Selective labeling and localization of the M4 (m4) muscarinic receptor subtype.
    Ferrari-Dileo G, Waelbroeck M, Mash DC, Flynn DD.
    Mol Pharmacol; 1994 Dec 15; 46(6):1028-35. PubMed ID: 7808421
    [Abstract] [Full Text] [Related]

  • 27. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors.
    Tränkle C, Weyand O, Schröter A, Mohr K.
    Mol Pharmacol; 1999 Nov 15; 56(5):962-5. PubMed ID: 10531401
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Mixed competitive and allosteric antagonism by gallamine of muscarinic receptor-mediated second messenger responses in N1E-115 neuroblastoma cells.
    Lee NH, el-Fakahany EE.
    J Neurochem; 1989 Oct 15; 53(4):1300-8. PubMed ID: 2549200
    [Abstract] [Full Text] [Related]

  • 31. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands.
    Buller S, Zlotos DP, Mohr K, Ellis J.
    Mol Pharmacol; 2002 Jan 15; 61(1):160-8. PubMed ID: 11752217
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Chimeric m2/m3 muscarinic receptors: role of carboxyl terminal receptor domains in selectivity of ligand binding and coupling to phosphoinositide hydrolysis.
    Wess J, Bonner TI, Brann MR.
    Mol Pharmacol; 1990 Dec 15; 38(6):872-7. PubMed ID: 2174507
    [Abstract] [Full Text] [Related]

  • 34. Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors.
    Tränkle C, Mohr K.
    Mol Pharmacol; 1997 Apr 15; 51(4):674-82. PubMed ID: 9106634
    [Abstract] [Full Text] [Related]

  • 35. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
    Matsui H, Lazareno S, Birdsall NJ.
    Mol Pharmacol; 1995 Jan 15; 47(1):88-98. PubMed ID: 7838137
    [Abstract] [Full Text] [Related]

  • 36. Structural basis of the subtype selectivity of muscarinic antagonists: a study with chimeric m2/m5 muscarinic receptors.
    Wess J, Gdula D, Brann MR.
    Mol Pharmacol; 1992 Feb 15; 41(2):369-74. PubMed ID: 1538713
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Complex allosteric modulation of cardiac muscarinic receptors by protamine: potential model for putative endogenous ligands.
    Hu J, Wang SZ, Forray C, el-Fakahany EE.
    Mol Pharmacol; 1992 Aug 15; 42(2):311-21. PubMed ID: 1513329
    [Abstract] [Full Text] [Related]

  • 39. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
    Cembala TM, Sherwin JD, Tidmarsh MD, Appadu BL, Lambert DG.
    Br J Pharmacol; 1998 Nov 15; 125(5):1088-94. PubMed ID: 9846649
    [Abstract] [Full Text] [Related]

  • 40. Molecular rigidity and potency of bispyridinium type allosteric modulators at muscarinic M2-receptors.
    Tränkle C, Elis K, Wiese M, Mohr K.
    Life Sci; 1997 Nov 15; 60(22):1995-2003. PubMed ID: 9180353
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.